Temgesic 0.2 mg resoriblett

Temgesic is a specialized analgesic medication containing buprenorphine, primarily used for the treatment of severe pain. The brand has deep roots in the United Kingdom, where it was developed by Reckitt Benckiser (then Reckitt & Colman) in the 1960s and 1970s. For many decades, it served as a cornerstone of their pharmaceutical portfolio, helping to pioneer sublingual administration for opioid treatments.

In recent years, the distribution and marketing rights for Temgesic in specific European markets, including the Nordic region seen in the image, have been transferred to Eumedica. While the brand was born in the UK, its manufacturing is now conducted across various European facilities to ensure supply for the regional markets. Today, the ultimate ownership of the brand reflects a transition from the original consumer goods giant to Eumedica, a pharmaceutical company focused on maintaining the availability of essential legacy medicines.